Get informed when a big investor buys or sells
+ Follow-15.49%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Aurora Cannabis R (21P.F) currently reports a ROE of -15.49%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Aurora Cannabis R's ROE history and peer comparisons.
Aurora Cannabis R's ROE of -15.49% is lower than the Healthcare sector average of 13.1%. That is roughly 218.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Aurora Cannabis R's current -15.49% should be judged against Healthcare norms (sector average: 13.1%) and against 21P.F's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -15.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Aurora Cannabis R, and consider following 21P.F for alerts when major investors trade the stock.
Aurora Cannabis R is classified in the Healthcare sector. On ROE, it currently shows -15.49% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 21P.F with unrelated industries.